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Purpose: We investigated the effect of propiverine on cystometric parameters based 
on intraabdominal pressure (IAP) in awake rats in an overactive bladder (OAB) model 
induced by intravesical instillation of prostaglandin E2 (PGE2).
Materials and Methods: Twenty-two female Sprague-Dawley rats were used. Polyeth-
ylene catheters were implanted into the bladder to record the intravesical pressure 
(IVP) and into the femoral artery to administer medication. A balloon-fitted catheter 
was positioned in the abdominal cavity to record the IAP. Awake cystometries were 
performed before and after intraarterial administration of propiverine 1 mg/kg (n=6), 
intravesical administration of 50μM PGE2 only (n=6), or intravesical PGE2 plus 1 
mg/kg (n=4) or 3 mg/kg (n=6) of intraarterial propiverine. Cystometric pressure and 
volume parameters and variables related to detrusor overactivity (DO) were 
investigated.
Results: Rats administered intravesical PGE2 showed increased pressure parameters 
and decreased volume parameters comparable to the DO model, which was effectively 
prevented by propiverine (1 or 3 mg/kg). Typical DO shown during the filling phase was 
decreased by intraarterial propiverine (3 mg/kg) injection. After propiverine (3 mg/kg) 
injection, IAP was increased at the time of micturition pressure with or without thresh-
old pressure (p＜0.05, p＜0.01) depending on the dose administered.
Conclusions: Propiverine improved pressure- and volume-related parameters in an 
OAB model. Furthermore, it also decreased the frequency of DO. However, higher con-
centrations of propiverine induced straining voiding.
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INTRODUCTION
Overactive bladder (OAB) is a highly prevalent disease 
that increases with age [1]. Its impact on the quality of life 
is similar to that of hypertension and diabetes and is more 
serious than that of depression [2]. For these reasons, OAB 
has an important position in the international drug 
industry. Although OAB patients show many variable 
symptoms, the central symptom of OAB is urgency [3,4], 
which is closely related to detrusor overactivity (DO) dur-
ing the filling phase in cystometry [5-7]. It was reported 
that 83% of patients with DO showed urgency, and 64% of 
patient with urgency showed DO [7]. Thus, it is important 
to observe DO objectively in clinical and research studies 
of OAB. Recently, we investigated nonvoiding contractions 
in awake animal models by simultaneous registrations of 
intravesical pressure (IVP) and intraabdominal pressure 
(IAP) [8].
Anticholinergic therapy is the first-line treatment op-
tion for patients with OAB, owing to the parasympathetic 
activation of the detrusor contractions [5]. Anticholinergic 
drugs suppress the involuntary detrusor contractions 
through competition with acetylcholine for the muscarinic 
receptors during both the storage and the voiding phase 
[3,9,10]. However, it is known experimentally that these 
drugs have no effects on voiding contraction and residual 
volume, because the amount of acetylcholine released dur-
ing the voiding phase is much more than those of anti-Korean J Urol 2010;51:64-69
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cholinergic drugs [10]. However, in clinical studies, some 
patients complained of straining voiding, increased re-
sidual volume, and sometimes acute urinary retention. 
This suggests that anticholinergics may have an influence 
on detrusor contractions during the voiding phase [11]. Up 
to now, there has been no experimental evaluation of the 
effect of anticholinergics during the voiding phase in awake 
rats by simultaneous registrations of IVP and IAP.
The objective of this study was therefore to perform si-
multaneous registrations of IVP and IAP to evaluate the 
effects of propiverine 1 and 3 mg/kg on DO during the filling 
phase and on abdominal straining during the voiding 
phase in awake rats with intravesical prostaglandin E2 
(PGE2) instillation.
MATERIALS AND METHODS
1. Animals
A total of 22 Sprague-Dawley (SD) female rats weighing be-
tween 200 and 250 g were used in this study. All procedures 
were performed in accordance with the Guide for the Care 
and Use of Laboratory Animals of the National Institutes 
of Health and were approved by the Inha-University 
Animal Ethics Committee. The rats were maintained un-
der standard laboratory conditions with a 12:12 h light: 
dark cycle and with free access to food pellets and tap water. 
Simultaneous IVP and IAP were continuously recorded 
during bladder filing and emptying as described previously 
[12].
2. Bladder, intraabdominal, and intraarterial catheter 
implantation
In brief, SD rats were anesthetized with ketamine 
(Ketamine; Yuhan Corp, Seoul, Korea; 75 mg/kg intra-
peritoneally) and xylazine (Rompun; Bayer Korea Corp, 
Korea; 15 mg/kg intraperitoneally). Through a low abdomi-
nal incision, a polyethylene catheter (PE-50; Becton 
Dickinson, Parsippany, USA) with a cuff was inserted into 
the dome of the bladder and was held in place with a 
purse-string suture. To record IAP, an abdominal balloon 
(Latex; Daewoo Medical, Incheon, Korea) around the cuff 
of a catheter tip was placed 1 cm proximal to the bladder 
along the catheter to the bladder and was attached with a 
silk tie to the catheter. A catheter (PE-10; Becton Dicki-
nson) was inserted into the femoral artery. These catheters 
were tunneled subcutaneously and anchored to the skin of 
the back with a silk ligature.
3. Cystometric investigations
Cystometry was performed 3 days after implantation of the 
catheters in unanesthetized, unrestrained rats in metabol-
ic cages. The indwelling catheter to the bladder was con-
nected to a two-way valve that was connected via a T-tube 
to a pressure transducer (Research Grade Blood Pressure 
Transducer; Harvard Apparatus, Holliston, USA) and a 
microinjection pump (PHD22/2,000 pump; Harvard Appa-
ratus). Another catheter connected to an air-free abdomi-
nal balloon was connected to another pressure transducer 
to record the IAP. Micturition volumes were recorded by 
means of a fluid collector connected to a force displacement 
transducer (Research Grade Isometric Transducer; Har-
vard Apparatus). Room-temperature saline was infused 
into the bladder continuously at a rate of 10 ml/h. IVP, IAP, 
and micturition volumes were recorded continuously with 
Acq Knowledge 3.8.1 software and an MP150 data acquis-
ition system (BIOPAC Systems, Goleta, USA) at a sam-
pling rate of 100 Hz. The mean values from three reprodu-
cible micturition cycles were used for evaluation. IAP was 
defined as the recorded balloon pressure corrected by sub-
tracting the lowest balloon pressure in each voiding cycle, 
which is comparable to zeroing in human cystometry. 
Detrusor pressure (DP) was defined as IVP minus IAP. The 
IVP rises during the filling phase (IVPRs) were defined as 
increments of IVP that exceeded 2 cmH2O from baseline, 
which was interpreted as abdominal straining if occurring 
with simultaneous similar changes in IAP, or as DO if oc-
curring without simultaneous similar changes in IAP [12].
The following conventional urodynamic pressure-vol-
ume parameters were investigated: micturition pressure 
(MP, maximum bladder pressure during micturition), bas-
al pressure (BP, the lowest bladder pressure during filling), 
threshold pressure (TP, bladder pressure immediately be-
fore micturition), bladder capacity (BC, residual volume at 
the most recent previous micturition plus the volume of in-
fused saline at micturition), micturition volume (MV, vol-
ume of expelled urine), residual volume (RV, bladder ca-
pacity minus micturition volume), and micturition inter-
val (MI, time between micturition events). Pressure pa-
rameters were respectively measured in IVP, IAP, and DP.
The following DO-related parameters during the filling 
phase were observed: time of filling phase (interval be-
tween the end of a micturition and the point immediately 
before the next micturition), total number of DO, frequency 
of DO per minute, and increased amplitude of DO as IVP. 
 In all groups, a period of about 30-60-min micturition cy-
cles was observed and the values from reproducible mictur-
ition cycles were used for evaluation.
4. Administration of drug
Stock solutions (0.01 M) of PGE2 (Sigma Chemical Co., St 
Louis, USA) were made in absolute ethanol and were then 
diluted to 50μM in saline just before use. PGE2 was infused 
intravesically at a rate of 10 ml/h. Propiverine 1 or 3 mg/kg 
was infused into the femoral artery after the baseline 
cystometry.
The rats were randomly allocated to the following four 
treatment groups after control cystometries with saline: 1) 
intraarterial propiverine 1 mg/kg only (n=6), 2) intra-
vesical PGE2 only (n=6), 3) intravesical PGE2 and intra-
arterial propiverine 1 mg/kg (n=4), or 4) intravesical PGE2 
and intraarterial propiverine 3 mg/kg (n=6).
5. Statistical analysis
The results are given as mean values±standard errors of Korean J Urol 2010;51:64-69
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TABLE 3. Effects of intraarterial administration of propiverine on 
cystometric pressure parameters by intravesical and detrusor 
pressures in conscious Sprague-Dawley rats with intravesical in-
stillation of PGE2
BP (cmH2O) TP (cmH2O) MP (cmH2O)
Baseline (n=16)
IVP
DP
8.47±0.71
6.92±0.28
24.19±1.34
19.93±2.04
    58.0±2.55
  55.20±2.52
PGE2 50μM (n=6)
IVP
DP
13.3±1.21
b
12.3±1.10
b
  29.8±1.68
a
  24.3±2.16
a
  108.9±8.62
b
100.13±6.06
b
Propiverine 1 mg/kg＋PGE2 50μM (n=4)
IVP
DP
8.65±0.69
c
8.25±0.48
28.18±1.34
25.14±1.84
  98.51±4.85
b
  86.57±7.42
b
Propiverine 3 mg/kg＋PGE2 50μM (n=6)
IVP
DP
8.04±0.71
c
7.02±0.76
c
28.96±1.25
20.09±2.11
  107.7±3.22
b
  90.27±8.03
b
BP: basal pressure, TP: threshold pressure, MP: micturition pres-
sure, IVP: intravesical pressure, DP: detrusor pressure. Results 
are expressed as mean±standard error of the mean. 
a: p＜0.05, 
b: p＜0.01 (unpaired Student’s t-test), versus baseline, 
c: p＜0.01
(unpaired Student’s t-test), versus PGE2 50μM.
TABLE 1. Effects of intraarterial administration of propiverine on cystometric parameters in conscious, normal Sprague-Dawley rats
BP
(cmH2O)
TP
(cmH2O)
MP
(cmH2O)
BC
(ml)
VV
(ml)
RV
(ml)
MI
(min)
Baseline (n=6)
IVP
DP
IAP
9.6±1.3
8.5±1.2
1.4±0.2
25.1±2.1
16.2±2.0
  9.0±1.4
52.7±4.0
49.2±3.7
  3.5±0.7
1.12±0.12 1.10±0.12 0.02±0.01 6.41±0.47
Propiverine 1 mg/kg (n=6)
IVP
DP
IAP
9.8±1.1
8.7±1.1
1.1±0.2
25.1±1.8
15.7±1.5
  9.4±0.8
57.0±5.8
52.3±5.7
  4.7±0.7
1.11±0.12 1.09±0.12 0.01±0.01 6.52±0.60
BP: basal pressure, TP: threshold pressure, MP: micturition pressure, BC: bladder capacity, VV: voided volume, RV: residual volume,
MI: micturition interval, IVP: intravesical pressure, DP: detrusor pressure, IAP: intraabdominal pressure. Results are expressed as
mean±standard error of the mean. There was no statistical differences between baseline and propiverine 1 mg group in urodynamic 
parameters.
TABLE 2. Effects of intraarterial administration of propiverine on 
intraabdominal pressures in conscious Sprague- Dawley rats 
with intravesical instillation of PGE2
BP
(cmH2O)
TP
(cmH2O)
MP
(cmH2O)
Baseline (n=16)
PGE2 50μM (n=6)
Propiverine 1 mg/kg
 ＋PGE2 50μM (n=4)
Propiverine 3 mg/kg
 ＋PGE2 50μM (n=6)
1.31±0.11
0.94±0.24
1.40±0.23
1.35±0.22
5.37±0.39
5.48±0.73
6.52±0.75
9.20±1.55
2.80±0.29
3.79±0.76
4.19±0.43
4.43±0.38
a
BP: basal pressure, TP: threshold pressure, MP: micturition 
pressure. Results are expressed as mean±standard error of the 
mean. 
a: p＜0.05 (unpaired Student’s t-test), versus baseline
the mean (SEMs). Normal distributions were confirmed by 
use of SigmaStat 2.0 (SPSS Inc, Chicago, USA). Statistical 
significance was determined by paired or unpaired t-tests. 
Statistical significance was defined as p＜0.05.
RESULTS
1. Effects of propiverine 1 mg/kg on normal rats
There were no significance differences in pressure- or vol-
ume-related parameters before and after the admin-
istration of propiverine 1 mg/kg in normal rats. Thus, we 
showed that propiverine 1 mg/kg had no effect on pres-
sure-volume parameters in normal rats (Table 1).
2. Effects of PGE2 with or without propiverine on IAP re-
corded at the points of BP, TP, and MP
The rats showed no changes in IAP recorded at the point 
of BP, TP, or MP after intravesical instillation of PGE2 50 
μM compared with baseline cystometries. The rats ad-
ministered intravesical PGE2 50μM and simultaneous in-
traarterial propiverine 1 mg/kg also showed no changes in 
IAP at those three points compared with baseline and 
PGE2-instilled cystometries. The rats administered intra-
vesical PGE2 50μM and simultaneous intraarterial propi-
verine 3 mg/kg showed increased IAP at MP (p＜0.05) only 
compared with baseline cystometries (Table 2).
3. Effects of PGE2 with or without propiverine on pres-
sure-related parameters
Recorded as IVP or DP, OAB was successfully induced in 
rats by intravesical instillation of PGE2, which resulted in 
increases in BP, TP, and MP compared with baseline cys-
tometries (p＜0.01, p＜0.05, and p＜0.01, respectively). 
The rats administered PGE2 and propiverine 1 mg/kg 
showed decreased BP by IVP (p＜0.01), compared with 
PGE2-instilled cystometries, and decreased MP by IVP and 
DP (p＜0.01, p＜0.01), compared with baseline cysto-
metries. The rats administered PGE2 and propiverine 3 
mg/kg showed decreased BP by IVP and DP (p＜0.01 and Korean J Urol 2010;51:64-69
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TABLE 4. Effects of intraarterial administration of propiverine on cystometric volume parameters in conscious Sprague-Dawley rats
with intravesical instillation of PGE2
BC (ml) VV (ml) RV (ml) MI (min)
Baseline (n=16)
PGE2 50μM (n=6)
Propiverine 1 mg/kg＋PGE2 50μM (n=4)
Propiverine 3 mg/kg＋PGE2 50μM (n=6)
1.25±0.08
0.84±0.19
a
0.98±0.13
0.91±0.05
1.25±0.08
0.84±0.19
a
0.98±0.12
0.91±0.05
0
0
0
0
7.34±0.46
5.18±0.83
a
5.73±0.82
5.50±0.11
BC: bladder capacity, VV: voided volume, RV: residual volume, MI: micturition interval. Results are expressed as mean±standard error
of the mean. 
a: p＜0.05 (unpaired Student’s t-test), versus baseline
TABLE 5. Effects of intraarterial administration of propiverine on the cystometric parameters related to detrusor overactivity in con-
scious Sprague-Dawley rats with intravesical instillation of PGE2
Group
Filling phase
(min)
Total No. of DO Freq. DO. /min
Increased Pr of
DO Peak from
baseline
(IVP. cmH2O)
Baseline (n=16)
PGE2 50μM (n=6)
Propiverine 1 mg/kg＋PGE2 50μM (n=4)
Propiverine 3 mg/kg＋PGE2 50μM (n=6)
5.61±0.10
3.80±0.32
a
5.21±0.78
4.80±0.34
       0
7.50±1.82
a
6.91±7.41
a
  5.0±0.72
a
       0
  2.0±0.42
a
1.33±1.13
a
  1.2±0.21
a
     0
3.5±0.23
a
4.9±0.82
a
3.6±0.62
a
No.: number, DO: detrusor overactivity, Freq.: frequency, Pr: pressure, IVP: intravesical pressure. Results are expressed as 
Mean±standard error of the mean. 
a: p＜0.01, versus baseline. There was no significant differences among the groups of intravesical
PGE2 instillation with or without propiverine injection.
p＜0.01, respectively), compared with PGE2-instilled cys-
tometries, and decreased MP by IVP and DP (p＜0.01 and 
p＜0.01, respectively), compared with baseline cys-
tometries (Table 3).
4. Effects of PGE2 with or without propiverine on vol-
ume-related parameters
OAB was successfully induced in rats by intravesical in-
stillation of PGE2, which resulted in decreases in BC, VV, 
and MI without changes in RV, compared with baseline cys-
tometries (p＜0.05, p＜0.05, and p＜0.05, respectively). 
The rats administered PGE2 and propiverine 1 or 3 mg/kg 
showed no change in volume-related parameters com-
pared with baseline or PGE2-instilled cystometries (Table 
4).
5. Effects of PGE2 with or without propiverine on DO-re-
lated parameters
DO was not observed in baseline cystometries. After intra-
vesical instillations of PGE2, DO of 2.0±0.42 /min was ob-
served (p＜0.01) compared with baseline cystometries. 
However, DO was not significantly decreased after propi-
verine injection in rats with intravesical PGE2 instillation 
(Table 5).
DISCUSSION
OAB is known to include various different pathophysio-
logic mechanisms [13,14]. Recently, among those mecha-
nisms, special attention has been given to the sensory and 
afferent mechanisms [10,14]. Research on the new gen-
eration of OAB drugs is focused on the inhibition of afferent 
firing before the generation of a detrusor contraction dur-
ing the filling phase, whereas the present anticholinergic 
drugs suppress the afferent firing after the generation of 
DO [14].
The intravesical PGE2 instillation method, one of the 
OAB models, induces DO by the indirect activation of affer-
ent nerves in the bladder as well as the direct activation 
of detrusor muscle. Prostanoids are endogenous signaling 
molecules that are distributed in both human and rat 
bladder. When the bladder is injured or stimulated, the 
prostanoids activate capsaicin-sensitive afferents. Then, 
tachykinins are released from the afferents, which lower 
the threshold for afferent firing, and, finally, stimulate the 
detrusor to induce overactivity [15-17]. Experimentally, 
the tachykinins initiate a micturition reflex by stimulating 
NK1,NK2 receptors, and intravesical prostanoids can in-
duce DO in cystometry in vivo [14,16,17]. In our study, the 
cystometric features of OAB patients were successfully 
generated by intravesical prostanoids in rats, which 
showed increased BP, TP, and MP and decreased BC, MV, 
and MI.
The detrusor contraction is mainly caused by stimulat-
ing muscarinic receptors, and the M3 subtype in particular 
is believed to have the most major action for detrusor con-
traction [9,18]. In general, anticholinergic drugs inhibit in-
voluntary detrusor contraction during the storage phase, 
but they do not significantly affect contractions during the 
voiding phase, because the quantity of acetylcholine is sev-Korean J Urol 2010;51:64-69
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eral dozen times higher than that during the storage phase 
[10]. In the present study, propiverine significantly de-
creased BP only, the basal tension of the bladder, in the in-
travesical PGE2 group and showed no effect on MP, BC, VV, 
or MI. This might be partly related to the accumulation of 
continuously infused intravesical prostanoids in this rat 
model. However, we know that there were some effects of 
the propiverine, because this group showed no differences 
in pressure or volume parameters compared with the con-
trol group, unlike the intravesical PGE2 only instillation 
group.
If we look at the effects by different concentrations of 
propiverine on the PGE2-instilled state of rat bladder, pro-
piverine 3 mg/kg decreased BP by DP but not by IVP, where-
as propiverine 1 mg/kg showed no decrease in BP by either 
IVP or DP. This suggests that the higher dose of propiverine 
decreased the basal tension of the detrusor. This is not in 
accordance with previously reported studies, in which the 
investigators did not observe any difference in BP, but only 
in MP. We suspect that the reason for this is the difference 
in animal models. Our study is the first observation of pro-
piverine effects in the animal model of prostanoid-induced 
OAB [5,11]. The volume parameters were significantly de-
creased after PGE2 instillation and increased to the levels 
of control rats after propiverine injection. This suggests 
that propiverine inhibits the effects of PGE2, regardless of 
concentrations of propiverine. Also, DO was not seen in con-
trol rats, but was shown in PGE2-instilled animals. The 
propiverine showed no effects on the frequency or pressure 
of DO, which is in contrast with the conventional concept 
for anticholinergic drugs. We conclude that the propiverine 
did not have any effect on the DO in animal models of pros-
tanoid-induced OAB. This is supported by the fact that 
some anticholinergic drugs for OAB show no effects in some 
patients [5,18,19].
The side effects of anticholinergic drugs are well known 
and described through clinical and basic research. 
However, straining voiding, which is a complaint from 
some people taking anticholinergic medication, has not 
been well investigated in previous reports [19,20]. This 
symptom is a straining of the abdomen to void because of 
feeling difficulty in voiding or a sense of residual urine and 
could be related to urinary retention [21]. In the present 
study, we checked the grade of straining during the voiding 
phase by using our models. There were no differences in ab-
dominal straining on MP between the control rats and the 
PGE2-induced OAB model. Straining was not increased af-
ter infusion of propiverine 1 mg/kg but was significantly in-
creased after infusion of propiverine 3 mg/kg. This suggests 
that in the OAB model, taking a higher dose of anti-
cholinergic drugs showed more straining during voiding. 
This finding may be associated with acute urinary re-
tention and dysuria, which are among the complications of 
anticholinergic drugs. According to the study by Elisa et al, 
which was based on patient information collected by gen-
eral practitioners in the United Kingdom [21], increased 
risk of voiding difficulty and acute urinary retention were 
observed in patients administered anticholinergic drugs, 
and these patients should be closely monitored during the 
first 30 days of treatment for signs or symptoms of urinary 
retention. Therefore, the presence and significance of these 
symptoms need to be taken into consideration when eluci-
dating the side effects of anticholinergic drugs in future 
research.
CONCLUSIONS
Propiverine improved pressure and volume-related pa-
rameters in an OAB model induced by intravesical PGE2, 
showing that propiverine can inhibit the activation of blad-
der contractions and possibly providing experimental evi-
dence for decreased urgency symptoms after administra-
tion of propiverine in patients. Furthermore, propiverine 
also decreased the DO frequency. However, a higher con-
centration of propiverine induced straining voiding, sug-
gesting the need for clinical studies of the side effects of an-
ticholinergic drugs, which are still unknown.
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